Developing univariate neurodegeneration biomarkers with low-rank and sparse subspace decomposition.

Med Image Anal

School of Computing, Informatics, and Decision Systems Engineering, Arizona State University, P.O. Box 878809 Tempe, AZ 85287, USA. Electronic address:

Published: January 2021

AI Article Synopsis

  • The study investigates how cognitive decline in Alzheimer's disease is linked to brain structure changes detected through MRI.
  • It proposes a new method to quantify these morphological changes, focusing on the differences between patients with Alzheimer's and those who are cognitively unimpaired.
  • The results show that the developed univariate morphometry index (UMI) is more effective than traditional measures and could help in identifying the progression of Alzheimer's disease.

Article Abstract

Cognitive decline due to Alzheimer's disease (AD) is closely associated with brain structure alterations captured by structural magnetic resonance imaging (sMRI). It supports the validity to develop sMRI-based univariate neurodegeneration biomarkers (UNB). However, existing UNB work either fails to model large group variances or does not capture AD dementia (ADD) induced changes. We propose a novel low-rank and sparse subspace decomposition method capable of stably quantifying the morphological changes induced by ADD. Specifically, we propose a numerically efficient rank minimization mechanism to extract group common structure and impose regularization constraints to encode the original 3D morphometry connectivity. Further, we generate regions-of-interest (ROI) with group difference study between common subspaces of Aβ+AD and Aβ-cognitively unimpaired (CU) groups. A univariate morphometry index (UMI) is constructed from these ROIs by summarizing individual morphological characteristics weighted by normalized difference between Aβ+AD and Aβ-CU groups. We use hippocampal surface radial distance feature to compute the UMIs and validate our work in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. With hippocampal UMIs, the estimated minimum sample sizes needed to detect a 25% reduction in the mean annual change with 80% power and two-tailed P=0.05are 116, 279 and 387 for the longitudinal Aβ+AD, Aβ+mild cognitive impairment (MCI) and Aβ+CU groups, respectively. Additionally, for MCI patients, UMIs well correlate with hazard ratio of conversion to AD (4.3, 95% CI = 2.3-8.2) within 18 months. Our experimental results outperform traditional hippocampal volume measures and suggest the application of UMI as a potential UNB.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725891PMC
http://dx.doi.org/10.1016/j.media.2020.101877DOI Listing

Publication Analysis

Top Keywords

univariate neurodegeneration
8
neurodegeneration biomarkers
8
low-rank sparse
8
sparse subspace
8
subspace decomposition
8
alzheimer's disease
8
developing univariate
4
biomarkers low-rank
4
decomposition cognitive
4
cognitive decline
4

Similar Publications

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions worldwide, leading to cognitive and functional decline. Early detection and intervention are crucial for enhancing the quality of life of patients and their families. Remote Monitoring Technologies (RMTs) offer a promising solution for early detection by tracking changes in behavioral and cognitive functions, such as memory, language, and problem-solving skills.

View Article and Find Full Text PDF

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Neurol Neuroimmunol Neuroinflamm

January 2025

From the Neurology-Neuroimmunology Department (J.V.-Á., V.F., A.V., M. Castillo, M. Comabella), Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute; Autonomous University of Barcelona (M. Comabella), Spain; Department of Neurology with Institute of Translational Neurology (J.D.L.), University Hospital Münster, Germany; Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., Y.B.), Hospital Clinic de Barcelona; Fundación INCE (Iniciativa para las Neurociencias) (A.V.-C.), Madrid, Spain; Neurology Unit (A.D., S.M.), Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy; Neuroimmunology Program (S.L., Y.B., T.A.), Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona; Pediatric Neuroimmunology Unit (T.A.), Neurology Department, Sant Joan de Déu Children's Hospital, University of Barcelona; Girona Neuroimmunology and Multiple Sclerosis Unit (G.Á.B., L.R.), Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital; Neurodegeneration and Neuroinflammation research group (G.Á.B., A.Q.-V., L.R.), IDIBGI, Girona-Salt; Department of Medical Sciences (G.Á.B., L.R.), Faculty of Medicine, University of Girona; and Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS) (A.Q.-V., L.R.), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain.

Background And Objectives: The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD.

Methods: Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples.

View Article and Find Full Text PDF

Alterations in subcortical brain regions are linked to motor and non-motor symptoms in Parkinson's disease (PD). However, associations between clinical expression and regional morphological abnormalities of the basal ganglia, thalamus, amygdala and hippocampus are not well established. We analyzed 3D T1-weighted brain MRI and clinical data from 2525 individuals with PD and 1326 controls from 22 global sources in the ENIGMA-PD consortium.

View Article and Find Full Text PDF

Structural MRI Correlates of Anosognosia in Huntington's Disease.

J Huntingtons Dis

September 2024

Departments of Neurology and Division of Neurobiology, Department of Psychiatry JHUSOM, Baltimore, MD, USA.

Article Synopsis
  • Anosognosia, or a lack of awareness of symptoms, is prevalent in Huntington's disease (HD), but researchers have not fully understood its neuroanatomical causes.
  • The study utilized MRI data from 570 HD participants to analyze correlations between brain structures and the severity of anosognosia, measured through discrepancies in scores between patients and their caregivers.
  • Findings revealed that the volume of the globus pallidus, along with other brain regions, significantly correlates with anosognosia, indicating that neurodegeneration in both cortical and subcortical areas, especially the globus pallidus, plays a crucial role in this condition.
View Article and Find Full Text PDF
Article Synopsis
  • - Neurodegenerative retinal diseases like glaucoma and diabetic retinopathy involve the gradual death of retinal ganglion cells (RGCs), driven by mitochondrial dysfunction, oxidative stress, and decreased energy production.
  • - Familial dysautonomia (FD) also leads to RGC degeneration, revealing disruptions in mitochondrial structures and energy metabolism that may impact overall visual health, with specific changes in the serum and stool metabolomes indicating systemic deficiencies.
  • - The study investigated alterations in retinal metabolites and focused on dopaminergic amacrine cells, which influence RGC activity, using advanced techniques like NMR spectroscopy and mass spectrometry to link these changes to the progressive loss of RGCs in an FD mouse model.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!